Liver Disease Diagnostics Market Share, Size, Trends, Industry Analysis Report, By Diagnosis Technique (Imaging, Laboratory Tests, Endoscopy, Biopsy, Others); By End-Use (Hospitals, Laboratories, Others), By Regions; Segment Forecast, 2021 - 2028
- 出版日期：2021年3月
- Pages: 108
- Format: PDF
- Report ID: PM1810
- Base Year: 2020
- Historical Data: 2016 - 2019
Report Summary
The global liver disease diagnostics market was valued at USD 30.59 billion in 2020 and is expected to grow at a CAGR of 6.7% during the forecast period. A global rise in acute and chronic liver disorders is the most prominent factor responsible for the market growth for liver disease diagnostics. For instance, as per the estimates of the World Health Organization (WHO), in 2018, there were around 841,080 new cases of liver cancer and approximately 781,631 people died with it.
Moreover, advancements in rapid tests by the key players in the liver disease diagnostics market for a specific section of the population such as HIV-positive patients and pregnant women also boosted the market growth. In line with this, Abbott Labs, in February 2019, received a CE mark for its HBsAg 2 test. It is an easy-to-use, rapid test for the detection of hepatitis B in the market.
Know more about this report:样本页请求
产业动态
增长动力
Rising research & development spend towards accurate and early diagnosis for better patient outcomes have propelled the market growth for liver disease diagnostics. Key players in the market for liver disease diagnostics are focused on introducing innovative products and services to improve diagnosis time. In this line, in 2020, Roche Ltd received breakthrough device designation for its Elecsys GALAD product. The product was developed by the Roche Diagnostics Liver indication program to enhance diagnosis workflow and much-needed help for the healthcare practitioners to provide accurate information.
Moreover, the introduction of novel procedures to diagnose liver diseases is also likely to have a positive impact on the future growth of the market for liver disease diagnostics. Earlier, in 2017, Ortho Clinical Diagnostics developed a new innovative method for the measurement of Alanine Aminotransferase (ALT) using VITROS ALTV Slides, developed through dry slide technology. This new method has reduced the sample requirement, increased sensitivity, and enhanced diagnostics capabilities.
肝病诊断市场报告范围
市场主要根据诊断技术、最终用途和地区进行细分。
By Diagnosis Technique |
按最终用途 |
By Region |
|
|
|
Know more about this report:样本页请求
诊断技术洞察
In 2020, the imaging market segment held the liver disease diagnostics industry share, among all. Such a high share is attributed to an increasing number of strategic initiatives taken by key players in the marketplace to launch advanced imaging services. First lab tests are carried out using blood, and fluid samples to diagnose abnormalities in liver functioning. WhileCT扫描MRI和超声是诊断的无创成像技术。
按最终用途细分
2020年，医院市场在全球肝病诊断行业中占据最大份额。这一高比例归因于大多数患者依赖于医院，因为医院拥有更好的疾病诊断能力。医院还为患者提供最佳护理，并实现早期疾病诊断。此外，医疗基础设施的进一步发展也促进了该部门的增长前景。乐动娱乐官网
The laboratory market segment is projected to grow at the fastest growth rate over the assessment period of the liver disease diagnostics market. Several labs and institutes have introduced awareness initiatives to diagnose hepatic abnormalities. For instance, in 2017, Mylan Labs collaborated with the Delhi-based Institute of the liver and Biliary Sciences to carry out awareness programs. The collaboration aimed to provide appropriate disease screening and testing capabilities to over 1,000 patient-based in Delhi. It also carried out tests for Hepatitis B and C, and ALT.
地理概况
从地理上看，全球肝病诊断市场分为北美、亚太、欧洲、拉丁美洲、中东和非洲。北美是最大的收入贡献国，其次是欧洲和亚太地区。2019年，北美地区占全球肝病诊断市场的43%以上。
预计北美将在评估期内保持其主导地位。推动这种增长的地区因素包括关键参与者在研发方面的高投入。该地区有许多机构提供有关疾病诊断的信息，更好的临床设施也有望推动该地区肝病诊断市场的增长。例如，该地区获取姑息治疗.org，涉及与CT扫描、活检和内窥镜检查相关的姑息治疗计划。
Competitive Insight
肝病诊断市场的主要参与者正在实施多种策略，以开发创新技术来推进以患者为中心的护理。在肝病诊断行业运营的著名公司有Horiba Medical、Abbott、Fujifilm Corporation、Roche Ltd、Randox Laboratories Ltd、Boston Scientific Corporation、Thermo Fisher Scientific Inc.、Laboratory Corporation of America Holdings和Siemens Healthcare GmbH。乐动娱乐官网
